Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Summary

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

Conditions

• Dyslipidemia

Interventions

DRUG

LCP-AtorFen

40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia

DRUG

atorvastatin

dyslipidemia and mixed dyslipidemia

DRUG

fenofibrate

dyslipidemia and mixed dyslipidemia

Sponsors & Collaborators

• Veloxis Pharmaceuticals

  lead INDUSTRY

Principal Investigators

• Jeff Geohas, MD · Radiant Research

• Dennis McCluskey, MD · Radiant Research

• Harry Geisberg, MD · Radiant Research

• Chivers Woodruff, Jr, MD · Radiant Research

• Michael Noss, MD · Radiant Research

• Michele Reynolds, MD · Radiant Research

• James Zavoral, MD · Radiant Research

• Randall Severance, MD · Radiant Research

• Stephen Halpern, MD · Radiant Research

• Linda Murray, MD · Radiant Research

• Wayne Larson, MD · Radiant Research

• Timothy Howards, MD · Medical Affiliated Research Center, Inc.

• Cynthia Strout, MD · Coastal Carolina Research Center

• Mark Kipnes, MD · Diabetes and Glandular Research Center, Inc.

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-07-31

Primary Completion

2008-02-29

Completion

2008-07-31

Countries

• United States

Study Locations